On February 10, 2023, the tendering committee of the Federal Center for Planning and Organization of Medical Support summed up the results of three tenders for the supply of Koselugo (INN selumetinib) for patients with neurofibromatosis type 1, and Strensiq (INN Asfotase alpha) for enzyme replacement therapy. One application has been submitted for each auction, and all of them have been recognized as meeting the established requirements. Contracts will be concluded at the initial (maximum) price with AO Pharmatsevtichesky Import Export (JSC Pharmaceutical Import, Export).
It should be noted that on February 10, three more auctions were announced for the supply of Koselugo and Takhzyro (INN lanadelumab), a therapy for the prevention of recurrent attacks of hereditary angioedema, and Ilaris (INN canakinumab), an immunosuppressant. Applications for the supply of Takhzyro are accepted until February 13, and for Koselugo and Ilaris, until February 17.
